Synapses, neuromuscular junction and muscle
How signals cross synapses, how the neuromuscular junction works and fails, and how excitation becomes contraction in skeletal and smooth muscle.
By the end of this page you should be able to
- Describe chemical synaptic transmission and compare excitatory and inhibitory postsynaptic potentials.
- Describe the structure and function of the neuromuscular junction, including the safety margin.
- Explain excitation-contraction coupling and the sliding filament mechanism in skeletal muscle.
- Describe the length-tension relationship and the types of contraction.
- Compare excitation-contraction coupling in smooth muscle with skeletal muscle.
Synaptic transmission
At a chemical synapse an action potential reaching the terminal opens voltage-gated Ca channels (N and P/Q type). Ca entry triggers fusion of transmitter vesicles with the membrane through the SNARE proteins (synaptobrevin on the vesicle, syntaxin and SNAP-25 on the membrane), the target of botulinum toxin. Transmitter crosses the cleft, binds postsynaptic receptors, and is removed by enzymes, reuptake or diffusion. The synaptic delay is about 0.5 ms.
An excitatory postsynaptic potential (EPSP) is a small depolarisation, usually from Na entry through ligand-gated cation channels (glutamate at AMPA receptors). An inhibitory postsynaptic potential (IPSP) hyperpolarises or clamps the membrane near rest, usually by opening Cl channels (GABA-A, glycine) or K channels (GABA-B). Individual PSPs are graded and decay; the neuron fires only when their sum at the axon hillock reaches threshold. Summation can be temporal (repeated input from one synapse) or spatial (inputs from many synapses at once). Presynaptic inhibition reduces transmitter release from a terminal without changing the postsynaptic cell.
The neuromuscular junction
- Each skeletal muscle fibre has a single endplate. The motor nerve terminal holds vesicles of acetylcholine (ACh), each a quantum of about 5 000 to 10 000 molecules. Random release of single quanta at rest causes miniature endplate potentials.
- An action potential opens P/Q-type Ca channels; about 100 to 200 vesicles fuse at active zones.
- ACh binds nicotinic receptors on the crests of the junctional folds: pentamers (adult form two alpha, beta, delta, epsilon; fetal form has gamma instead of epsilon). Both alpha subunits must bind ACh to open the non-selective cation channel; Na entry dominates.
- The endplate potential (graded, large) triggers an action potential in the adjacent membrane, where voltage-gated Na channels crowd the depths of the folds.
- Acetylcholinesterase, anchored in the basal lamina, hydrolyses ACh to choline and acetate within about a millisecond. Choline is taken back up and reused (choline acetyltransferase).
- Safety margin: far more ACh is released, and far more receptors exist, than are needed. About 70 to 75% of receptors must be blocked before twitch strength falls, and about 90 to 95% for complete block.
When the junction fails
- Myasthenia gravis: antibodies against nicotinic receptors (or MuSK) reduce receptor numbers, eroding the safety margin. Fatigable weakness, worse with repetition; sensitive to non-depolarising blockers, resistant to suxamethonium.
- Lambert-Eaton syndrome: antibodies to presynaptic voltage-gated Ca channels, often with small cell lung cancer; weakness improves briefly with repeated effort; autonomic features.
- Botulism: toxin cleaves SNARE proteins, blocking ACh release: descending flaccid paralysis with autonomic features.
- Organophosphates: inhibit acetylcholinesterase: muscarinic excess, nicotinic fasciculation then weakness, and central effects.
- Drugs: non-depolarising blockers compete with ACh; suxamethonium depolarises then holds the membrane inexcitable; aminoglycosides and magnesium reduce ACh release.
Excitation-contraction coupling in skeletal muscle
The muscle action potential runs along the sarcolemma and down T tubules. In the T tubule membrane, dihydropyridine receptors (L-type Ca channels acting as voltage sensors) are mechanically linked to ryanodine receptors (RyR1) in the sarcoplasmic reticulum (SR). Depolarisation changes the DHP receptor shape, which opens RyR1, releasing Ca from the SR. Skeletal muscle does not need extracellular Ca to contract.
Ca binds troponin C, moving tropomyosin off the myosin-binding sites on actin. Myosin heads, already cocked by ATP hydrolysis, bind actin and perform the power stroke, releasing ADP and phosphate. A new ATP binds and detaches the head; hydrolysis recocks it. Relaxation needs ATP too: SERCA pumps Ca back into the SR. Without ATP, heads stay bound: rigor mortis.
Malignant hyperthermia is uncontrolled Ca release through abnormal RyR1 channels triggered by volatile anaesthetics and suxamethonium. Dantrolene blocks RyR1.
Sliding filaments and length-tension
The sarcomere runs from Z line to Z line. Thin actin filaments anchor at the Z line; thick myosin filaments sit in the A band (constant length); the I band (actin only) and H zone (myosin only) shorten during contraction as filaments slide past each other. Titin gives passive elasticity.
Active tension depends on overlap: maximal at a sarcomere length of about 2.0 to 2.2 µm, falling when stretched (fewer cross-bridges) or shortened (filaments collide). Skeletal muscle normally works near its optimum. Cardiac muscle works on the ascending limb, which is the cellular basis of the Frank-Starling mechanism.
- Isometric: tension without shortening. Isotonic: shortening at constant load (concentric) or lengthening under load (eccentric).
- Summation and tetanus: the twitch outlasts the action potential, so repeated stimulation summates; at high frequency, a fused tetanus.
- Force-velocity: the heavier the load, the slower the shortening.
Smooth muscle
Smooth muscle has no troponin and no sarcomeres; actin and myosin attach to dense bodies. Ca enters through L-type channels and is released from SR by IP3 (Gq receptors). Ca binds calmodulin, which activates myosin light chain kinase (MLCK); phosphorylated myosin light chains allow cross-bridge cycling. Myosin light chain phosphatase reverses it. The latch state keeps tone with little ATP use.
This explains drug effects: cAMP (beta-2 agonists) inhibits MLCK, relaxing bronchial muscle; cGMP (nitric oxide, nitrates) activates the phosphatase, relaxing vascular muscle; Rho kinase inhibits the phosphatase, increasing Ca sensitivity.
Making the answer flow
- Walk the NMJ in order: nerve action potential, Ca entry, vesicle release, receptor binding, endplate potential, muscle action potential, breakdown. Draw it.
- Quote the safety margin with numbers; it explains train-of-four monitoring and myasthenia.
- Contrast skeletal and smooth muscle coupling in one table: trigger, Ca source, Ca sensor, regulation.
Where marks are lost
- Saying skeletal muscle needs Ca entry from outside to contract. The DHP-RyR1 link is mechanical.
- Saying relaxation is passive. SERCA uses ATP.
- Forgetting that both alpha subunits must bind ACh.
- Giving smooth muscle troponin. It uses calmodulin and MLCK.
Where this meets surgical practice
- Suxamethonium can cause dangerous hyperkalaemia in patients with burns, crush injury or denervation.
- Smooth muscle of the gut is controlled by the enteric nervous system; opioids slow motility and prolong postoperative ileus.
Test yourself
Answer each one aloud or on paper before you open the model points; explaining the mechanism is what makes the MCQ options easy to judge.
- 1.
Describe the events at the neuromuscular junction from the arrival of the action potential to contraction of the muscle.
Show answer
- Action potential depolarises terminal; P/Q-type voltage-gated Ca channels open.
- Ca triggers SNARE-mediated exocytosis of ACh vesicles at active zones.
- ACh binds nicotinic receptors (two alpha subunits); cation channel opens; endplate potential.
- Endplate potential exceeds threshold; voltage-gated Na channels in fold depths fire a muscle action potential.
- Acetylcholinesterase hydrolyses ACh; choline reuptake.
- Muscle action potential spreads via T tubules to excitation-contraction coupling.
- 2.
What is the safety margin of neuromuscular transmission and why does it matter clinically?
Show answer
- More ACh released and more receptors present than needed to reach threshold.
- About 70 to 75% of receptors must be blocked before twitch height falls; 90 to 95% for complete block.
- A normal single twitch or train-of-four ratio does not exclude significant receptor occupancy; residual blockade risks aspiration and hypoxia.
- In myasthenia the margin is already reduced, so non-depolarising agents have exaggerated effects.
- 3.
Explain excitation-contraction coupling in skeletal muscle.
Show answer
- Action potential along sarcolemma and into T tubules.
- DHP receptors (voltage sensors) mechanically open RyR1 in SR terminal cisternae.
- Ca binds troponin C, tropomyosin moves, myosin binding sites exposed.
- Cross-bridge cycling: attach, power stroke, ATP binding detaches, hydrolysis recocks.
- Relaxation: SERCA pumps Ca back into SR (ATP-dependent); calsequestrin stores Ca.
- 4.
How does smooth muscle contraction differ from skeletal muscle contraction?
Show answer
- Trigger: neural, hormonal, stretch or pacemaker; may not need an action potential (pharmacomechanical coupling via IP3).
- Ca from extracellular fluid (L-type channels) and SR (IP3 receptors).
- Ca-calmodulin activates MLCK; phosphorylation of myosin light chain needed; no troponin.
- Slow, sustained, economical (latch state); regulated by MLC phosphatase and Rho kinase.
- Drug targets: beta-2 agonists (cAMP), nitrates (cGMP), calcium channel blockers.
- 5.
Compare myasthenia gravis and Lambert-Eaton syndrome.
Show answer
- MG: postsynaptic, antibodies to nicotinic receptors or MuSK; fatigable weakness, ocular and bulbar common; decremental response on repetitive stimulation; improves with anticholinesterase.
- LEMS: presynaptic, antibodies to voltage-gated Ca channels; proximal leg weakness, reduced reflexes, autonomic dysfunction; strength and reflexes briefly improve with exercise; incremental response at high-frequency stimulation; associated with small cell lung cancer.
- Both are sensitive to non-depolarising blockers.
- 6.
Describe the length-tension relationship in skeletal muscle and relate it to the heart.
Show answer
- Active tension depends on actin-myosin overlap; maximal at sarcomere length about 2.0 to 2.2 µm.
- Falls with stretch (less overlap) and with shortening (filaments overlap and collide, thick filaments hit Z lines).
- Passive tension (titin, connective tissue) rises steeply with stretch.
- Cardiac muscle works on the ascending limb: more stretch, more force, plus increased Ca sensitivity with stretch: the Frank-Starling mechanism.
- 7.
What is malignant hyperthermia? Explain the physiology and treatment.
Show answer
- Inherited (autosomal dominant) defect, usually in RyR1, sometimes in the DHP receptor.
- Triggers: volatile anaesthetics and suxamethonium; uncontrolled SR Ca release.
- Sustained contraction, hypermetabolism: rising end-tidal CO2, tachycardia, rigidity, hyperthermia, acidosis, hyperkalaemia, rhabdomyolysis.
- Treatment: stop triggers, dantrolene (blocks RyR1), cooling, treat hyperkalaemia and arrhythmias.
- 8.
Explain the difference between an EPSP and an IPSP and how a neuron decides whether to fire.
Show answer
- EPSP: depolarisation from cation entry (glutamate at AMPA or NMDA receptors).
- IPSP: hyperpolarisation or shunting via Cl (GABA-A, glycine) or K channels (GABA-B).
- Graded, decremental, summate temporally and spatially at the axon hillock (lowest threshold, most Na channels).
- Neuron fires if net depolarisation reaches threshold; benzodiazepines and propofol enhance IPSPs.
- 9.
How does organophosphate poisoning cause weakness?
Show answer
- Organophosphates phosphorylate and inhibit acetylcholinesterase; may age (irreversible).
- ACh accumulates at the NMJ: fasciculations, then depolarising block and weakness (including respiratory muscles).
- Muscarinic (bronchorrhoea, bronchospasm, bradycardia, salivation, miosis) and central effects (seizures, coma).
- Treatment: atropine for muscarinic effects (titrated to dry chest), supportive ventilation; atropine does not reverse nicotinic weakness. Intermediate syndrome can follow days later.
Practise this week
Week 22 in the other subjects
- Anatomy: Cranial nerves and the orbit
- Pathology: Endocrine pathology
Not affiliated with the Royal Australasian College of Surgeons. Notes are a revision aid, not a substitute for the curriculum or for clinical guidelines.